WASHINGTON (AP) — When a Halloween party sparked a COVID-19 outbreak at North Carolina Agricultural and Technical State University, school officials conducted rapid screening on more than 1,000 students in a week, including many who didn’t have symptoms.
Although such asymptomatic screening isn’t approved by regulators and the 15-minute tests aren’t as sensitive as the genetic one that can take days to yield results, the testing director at the historically Black college credits the approach with quickly containing the infections and allowing the campus to remain open.
LONDON (AP) — The U.K. government announced Friday that it plans to work with a German biopharmaceutical company to develop vaccines targeting emerging variants of COVID-19 as public health officials call for new tools to keep the virus in check as it mutates.
Dr. Robin Larabee was thrilled to start offering coronavirus testing at her pediatrics practice in Denver last fall. Testing for children is often scarce, and her new machines could return results within minutes.
She quickly discovered an unexpected obstacle: a major health insurer that paid her less than the cost of the test itself. Each kit Dr. Larabee purchased for her machines cost about $41, but the insurer sent back half that amount each time she submitted a claim.
TORONTO — As frustration mounts in Canada at the leaden weight of lockdowns and the glacial pace of vaccinations, a consortium of some of the country’s largest companies has launched a rapid testing program with the aim of protecting their 350,000 employees and publishing a playbook for businesses across Canada on how to reopen safely.
The program is believed to be the first of its kind among the Group of 7 industrialized nations, and has already attracted the attention of the Biden administration.
Nearly a year into the coronavirus pandemic, as thousands of patients are dying every day in the United States and widespread vaccination is still months away, doctors have precious few drugs to fight the virus.
A handful of therapies — remdesivir, monoclonal antibodies and the steroid dexamethasone — have improved the care of Covid patients, putting doctors in a better position than they were when the virus surged last spring. But these drugs are not cure-alls and they’re not for everyone, and efforts to repurpose other drugs, or discover new ones, have not had much success.
Lab-made antibodies are showing promise for preventing Covid-19 infection in those at high risk of contracting the disease. With vaccines in short supply in the United States and elsewhere, the drugs could be used to provide short-term protection until people can get vaccinated.
